<p>Rapt Therapeutics（NASDAQ:RAPT - 獲取免費報告）的股票在覆蓋該公司的十四家券商中獲得了 “適度買入” 的平均評級，MarketBeat 報告稱。一位投資分析師對該股票給予了賣出建議，兩位給予了持有建議，九位給予了買入建議，另外兩位則對該公司給予了強烈買入建議。在過去一年中，對該股票發佈評級的券商的平均一年目標價為 55.4444 美元。</p>
<p>RAPT 最近成為多份分析師報告的主題。富國銀行在 11 月 3 日的研究報告中對 Rapt Therapeutics 設定了 72.00 美元的目標價，並給予該股票 “超配” 評級。Leerink Partners 在 9 月 25 日的研究報告中將 Rapt Therapeutics 的評級從 “持有” 上調至 “強烈買入”。摩根大通在 11 月 12 日的研究報告中將 Rapt Therapeutics 的目標價從 55.00 美元上調至 57.00 美元，並給予該公司 “超配” 評級。Cowen 在 12 月 18 日的研究報告中開始覆蓋 Rapt Therapeutics 的股票，並對該公司設定了 “買入” 評級。最後，Piper Sandler 在週五的研究報告中開始覆蓋 Rapt Therapeutics 的股票，並設定了 “超配” 評級和 95.00 美元的目標價。</p>
<p>獲取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們最新的 RAPT 股票分析</strong></p>
<h2>Rapt Therapeutics 的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近修改了他們對 RAPT 的持股。Velan Capital Investment Management LP 在第三季度收購了 Rapt Therapeutics 的新頭寸，價值約為 2,063,000 美元。Susquehanna International Group LLP 在第三季度將其在 Rapt Therapeutics 的股份增加了 173.4%。Susquehanna International Group LLP 現在擁有 45,382 股該公司的股票，價值為 1,170,000 美元，此前在上個季度又收購了 28,782 股。Millennium Management LLC 在第三季度將其在 Rapt Therapeutics 的股份增加了 75.2%。Millennium Management LLC 現在擁有 39,278 股該公司的股票，價值為 1,013,000 美元，此前在此期間又收購了 16,854 股。Boone Capital Management LLC 在第三季度收購了 Rapt Therapeutics 的新頭寸，價值約為 20,180,000 美元。最後，Ameriprise Financial Inc. 在第三季度收購了 Rapt Therapeutics 的新頭寸，價值約為 1,326,000 美元。99.09% 的股票由機構投資者和對沖基金持有。</p>
<h2>Rapt Therapeutics 股票表現</h2>
<p>NASDAQ:RAPT 的股票在週三開盤價為 34.06 美元。該股票的 50 日簡單移動平均線為 32.31 美元，200 日簡單移動平均線為 22.63 美元。Rapt Therapeutics 的 52 周低點為 5.67 美元，52 周高點為 42.39 美元。該股票的市值為 9.438 億美元，市盈率為-3.08，貝塔值為 0.45。</p>
<p>Rapt Therapeutics（NASDAQ:RAPT - 獲取免費報告）最近在 11 月 6 日發佈了其財報。該公司報告季度每股收益（EPS）為（0.65）美元，超出分析師共識預期的（0.88）美元，超出幅度為 0.23 美元。整體來看，股票分析師預測 Rapt Therapeutics 在當前財年將發佈-2.14 的每股收益。</p>
<h2>關於 Rapt Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>RAPT Therapeutics, Inc NASDAQ: RAPT 是一家臨牀階段的生物技術公司，開發用於自身免疫和過敏性疾病的新型治療藥物。公司成立於 2013 年，總部位於加利福尼亞州聖地亞哥，RAPT 應用組織選擇性免疫學設計小分子和生物製劑候選藥物，以調節免疫細胞的遷移和組織駐留途徑。公司的研究平台能夠識別驅動組織炎症的靶點，旨在實現比當前療法更好的療效和安全性。</p>
<p>公司的主要資產 RPT193 是一種口服可用的 CC 化學趨化因子受體 4（CCR4）拮抗劑，目前正在進行特應性皮炎和過敏性哮喘的臨牀開發。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Rapt Therapeutics</li>
<li>股票即將迎來 “凶兆日”……</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>將這些代碼輸入到您的普通經紀賬户中</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
<li>特朗普剛剛簽署了</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Rapt Therapeutics 嗎？</h2>
<p>在你考慮 Rapt Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Rapt Therapeutics 並不在名單上。</p>
<p>雖然 Rapt Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RAPT

<p>Rapt Therapeutics（納斯達克代碼：RAPT）獲得了 14 家券商的 “適度買入” 共識評級。分析師的建議包括 1 個賣出、2 個持有、9 個買入和 2 個強力買入。1 年期的平均目標價格為 55.44 美元。最近的報告包括富國銀行的 72 美元目標價和摩根大通將目標價上調至 57 美元。該股票開盤價為 34.06 美元，市值為 9.438 億美元，52 周價格區間為 5.67 美元至 42.39 美元。Rapt 專注於開發針對自身免疫和過敏疾病的治療藥物，其主要資產 RPT193 正在進行臨牀開發</p>

<p>Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have earned an average rating of &#34;Moderate Buy&#34; from the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $55.4444.</p>
<div class="lb-trans"><p>Rapt Therapeutics（NASDAQ:RAPT - 獲取免費報告）的股票在覆蓋該公司的十四家券商中獲得了 “適度買入” 的平均評級，MarketBeat 報告稱。一位投資分析師對該股票給予了賣出建議，兩位給予了持有建議，九位給予了買入建議，另外兩位則對該公司給予了強烈買入建議。在過去一年中，對該股票發佈評級的券商的平均一年目標價為 55.4444 美元。</p>
</div><p>RAPT has been the subject of a number of recent analyst reports. Wells Fargo &amp; Company set a $72.00 price objective on Rapt Therapeutics and gave the stock an &#34;overweight&#34; rating in a research report on Monday, November 3rd. Leerink Partnrs upgraded Rapt Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, September 25th. JPMorgan Chase &amp; Co. boosted their price objective on Rapt Therapeutics from $55.00 to $57.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, November 12th. Cowen initiated coverage on shares of Rapt Therapeutics in a research report on Thursday, December 18th. They set a &#34;buy&#34; rating for the company. Finally, Piper Sandler started coverage on shares of Rapt Therapeutics in a research report on Friday. They set an &#34;overweight&#34; rating and a $95.00 price target on the stock.</p>
<div class="lb-trans"><p>RAPT 最近成為多份分析師報告的主題。富國銀行在 11 月 3 日的研究報告中對 Rapt Therapeutics 設定了 72.00 美元的目標價，並給予該股票 “超配” 評級。Leerink Partners 在 9 月 25 日的研究報告中將 Rapt Therapeutics 的評級從 “持有” 上調至 “強烈買入”。摩根大通在 11 月 12 日的研究報告中將 Rapt Therapeutics 的目標價從 55.00 美元上調至 57.00 美元，並給予該公司 “超配” 評級。Cowen 在 12 月 18 日的研究報告中開始覆蓋 Rapt Therapeutics 的股票，並對該公司設定了 “買入” 評級。最後，Piper Sandler 在週五的研究報告中開始覆蓋 Rapt Therapeutics 的股票，並設定了 “超配” 評級和 95.00 美元的目標價。</p>
</div><p>Get <strong>Rapt Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on RAPT</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 RAPT 股票分析</strong></p>
</div><h2>Institutional Trading of Rapt Therapeutics</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of RAPT. Velan Capital Investment Management LP acquired a new position in Rapt Therapeutics in the third quarter valued at about $2,063,000. Susquehanna International Group LLP increased its position in shares of Rapt Therapeutics by 173.4% during the third quarter. Susquehanna International Group LLP now owns 45,382 shares of the company's stock valued at $1,170,000 after acquiring an additional 28,782 shares during the last quarter. Millennium Management LLC raised its stake in shares of Rapt Therapeutics by 75.2% in the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company's stock valued at $1,013,000 after acquiring an additional 16,854 shares during the period. Boone Capital Management LLC acquired a new position in shares of Rapt Therapeutics in the 3rd quarter worth approximately $20,180,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Rapt Therapeutics in the 3rd quarter worth approximately $1,326,000. 99.09% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近修改了他們對 RAPT 的持股。Velan Capital Investment Management LP 在第三季度收購了 Rapt Therapeutics 的新頭寸，價值約為 2,063,000 美元。Susquehanna International Group LLP 在第三季度將其在 Rapt Therapeutics 的股份增加了 173.4%。Susquehanna International Group LLP 現在擁有 45,382 股該公司的股票，價值為 1,170,000 美元，此前在上個季度又收購了 28,782 股。Millennium Management LLC 在第三季度將其在 Rapt Therapeutics 的股份增加了 75.2%。Millennium Management LLC 現在擁有 39,278 股該公司的股票，價值為 1,013,000 美元，此前在此期間又收購了 16,854 股。Boone Capital Management LLC 在第三季度收購了 Rapt Therapeutics 的新頭寸，價值約為 20,180,000 美元。最後，Ameriprise Financial Inc. 在第三季度收購了 Rapt Therapeutics 的新頭寸，價值約為 1,326,000 美元。99.09% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Rapt Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 股票表現</h2>
</div><p>Shares of NASDAQ:RAPT opened at $34.06 on Wednesday. The stock's 50-day simple moving average is $32.31 and its two-hundred day simple moving average is $22.63. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $42.39. The stock has a market capitalization of $943.80 million, a price-to-earnings ratio of -3.08 and a beta of 0.45.</p>
<div class="lb-trans"><p>NASDAQ:RAPT 的股票在週三開盤價為 34.06 美元。該股票的 50 日簡單移動平均線為 32.31 美元，200 日簡單移動平均線為 22.63 美元。Rapt Therapeutics 的 52 周低點為 5.67 美元，52 周高點為 42.39 美元。該股票的市值為 9.438 億美元，市盈率為-3.08，貝塔值為 0.45。</p>
</div><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.88) by $0.23. As a group, equities analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Rapt Therapeutics（NASDAQ:RAPT - 獲取免費報告）最近在 11 月 6 日發佈了其財報。該公司報告季度每股收益（EPS）為（0.65）美元，超出分析師共識預期的（0.88）美元，超出幅度為 0.23 美元。整體來看，股票分析師預測 Rapt Therapeutics 在當前財年將發佈-2.14 的每股收益。</p>
</div><h2>About Rapt Therapeutics</h2>
<div class="lb-trans"><h2>關於 Rapt Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>RAPT Therapeutics, Inc NASDAQ: RAPT is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company's research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.</p>
<div class="lb-trans"><p>RAPT Therapeutics, Inc NASDAQ: RAPT 是一家臨牀階段的生物技術公司，開發用於自身免疫和過敏性疾病的新型治療藥物。公司成立於 2013 年，總部位於加利福尼亞州聖地亞哥，RAPT 應用組織選擇性免疫學設計小分子和生物製劑候選藥物，以調節免疫細胞的遷移和組織駐留途徑。公司的研究平台能夠識別驅動組織炎症的靶點，旨在實現比當前療法更好的療效和安全性。</p>
</div><p>The company's lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.</p>
<div class="lb-trans"><p>公司的主要資產 RPT193 是一種口服可用的 CC 化學趨化因子受體 4（CCR4）拮抗劑，目前正在進行特應性皮炎和過敏性哮喘的臨牀開發。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Rapt Therapeutics</li>
<li>“Ominous day” coming to stocks…</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>Trump just signed it</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Rapt Therapeutics</li>
<li>股票即將迎來 “凶兆日”……</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>將這些代碼輸入到您的普通經紀賬户中</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
<li>特朗普剛剛簽署了</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RAPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Rapt Therapeutics 嗎？</h2>
</div><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Rapt Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Rapt Therapeutics 並不在名單上。</p>
</div><p>While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rapt Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

RAPT Therapeutics（納斯達克代碼：RAPT）被分析師一致評為 “適度買入”